Boc-D-Tic(7-OH)-OH

Boc-D-Tic(7-OH)-OH is a Boc-protected D-configured amino acid building block derived from Tic, bearing a hydroxyl substituent at the 7-position of its side-chain. This protected, stereodefined form is commonly used in peptide and peptidomimetic synthesis workflows where controlled incorporation of a hydroxyl-functionalized, constrained residue is required. The Boc group provides a stable N-terminal protection strategy for stepwise assembly, while the side-chain hydroxyl enables downstream functionalization or retention of a hydrogen-bonding handle in the final scaffold.

1. Peptide Library Synthesis

Boc-D-Tic(7-OH)-OH is used by peptide chemistry groups to construct peptide libraries and analog series that probe how constrained, hydroxyl-bearing residues influence conformation and intermolecular interactions. The D stereochemistry and rigid side-chain framework are particularly valuable when researchers aim to diversify backbone stereochemical patterns while maintaining a defined residue geometry. The Boc-protected amino terminus supports routine protected-amino-acid handling during iterative coupling and purification, making it a practical choice for parallel synthesis and structure-activity relationship studies in medicinal chemistry.

2. Peptidomimetic Scaffold Building

Boc-D-Tic(7-OH)-OH serves as a targeted building block for peptidomimetic development, where the Tic-derived scaffold helps introduce structural constraint and a side-chain hydroxyl for interaction tuning. Medicinal chemistry and chemical biology teams often incorporate this residue into constrained analogs to create defined three-dimensional presentations of functional groups within larger peptide-like constructs. The hydroxyl substituent provides a chemically addressable site for later derivatization during scaffold optimization, while the Boc protection supports reliable assembly of multi-residue intermediates prior to final deprotection and purification.

3. Pharmaceutical Intermediate Development

Boc-D-Tic(7-OH)-OH is frequently selected in pharmaceutical intermediate workflows for preparing protected, stereochemically defined fragments that can be carried forward into larger coupling sequences. Process development and custom synthesis teams value the combination of a stable N-terminal protecting group with a side-chain functional handle, enabling controlled downstream transformations without disrupting the protected amino acid identity. This makes the reagent useful for generating well-defined intermediates used in custom peptide manufacturing research, where reproducible fragment quality and functional-group compatibility are central to scalable synthesis planning.

4. Late-Stage Side-Chain Functionalization

Boc-D-Tic(7-OH)-OH is applied when a hydroxyl-bearing amino acid residue is needed as a persistent functional motif that can be modified after peptide assembly. Chemical biology and materials-oriented peptide researchers can leverage the side-chain hydroxyl to introduce additional functionality through subsequent derivatization steps, supporting the preparation of functionalized peptide conjugates or specialized peptide materials. The Boc-protected starting form helps maintain synthetic control during assembly, allowing the hydroxyl to remain available as a handle for downstream modification strategies once the peptide framework is in place.

1. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

2. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

3. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

5. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide